

# Alexandre Loupy



## En Bref

Le Dr Alexandre Loupy est néphrologue au Département de néphrologie et de transplantation rénale de l'hôpital Necker à Paris, France. Il a rejoint le Paris Transplant Group en 2008.

## Biographie

Le Dr Alexandre Loupy a défendu son doctorat en médecine en 2008. Il a obtenu le Resident Award des Hôpitaux de Paris. Il a soutenu son doctorat en sciences fondamentales en 2011 et a obtenu un doctorat en biostatistique en 2014.

Ses travaux de recherche portent sur le rejet des allogreffes rénales par les anticorps et la relation avec les lésions histologiques des greffons, le vieillissement vasculaire à médiation immunitaire et les résultats des allogreffes. Le Dr Loupy a récemment mis au point une approche populationnelle de la transplantation à l'aide de nouveaux outils méthodologiques qui sont utilisés pour la stratification des risques. Cette nouvelle approche populationnelle de cohortes extrêmement bien phénotypées a été étendue aux cœurs, aux greffes pulmonaires et aux greffes d'organes.

Le Dr Loupy est membre de la Société française de transplantation et du Comité scientifique de la Conférence de Banff. En 2018, il est lauréat du Prix de l'Académie nationale de médecine et Vanity Fair France le place dans la liste des 50 Français les plus influents dans le monde.

---

## **Titres et Diplômes Universitaires**

- 2016 Habilitation à Diriger des Recherches, Université Paris Descartes
- 2013 Doctorat en sciences #2 : Épidémiologie et Santé Publique Paris Descartes
- 2011 Post doctorat : ATAGC Transplant Applied Genomics Center Edmonton, University of Alberta, Canada  
Doctorat en sciences #2: Biologie cellulaire : Université Paris Descartes
- 2008 Diplôme d'études spécialisées de Néphrologie  
Thèse de Doctorat en Médecine : mention très honorable, médaille d'argent, Université Paris V, France
- 2007 Mastère 2, Santé Univ Paris 7, Biologie Cellulaire, Physiologie et Pathologie Parcours « Epithéliums, modèles cellulaires et spécialisation » Pr Clerici.  
Hesperis European Course: Advanced Training in Organ Transplantation, European Society for Organ Transplantation  
École d'été en santé publique: Méthdologie en statistique et en épidémiologie
- 2005 Mastère M1: Epidémiologie et Recherche Clinique, Pr Bréart  
Mastère M1: Physiologie et Biologie des Systèmes Intégrés, Pr Paillard
- 2002 Internat des Hôpitaux de Paris, spécialités médicales

---

## **Titres Hospitaliers**

2014 – présent : MCUPH (Praticien Hospitalier Service de transplantation rénale Pr Ch. Legendre et valence universitaire en Épidémiologie Université Paris Descartes)

2013 – 2014 : Chef de Clinique Assistant en Épidémiologie. INSERM U970 – Hôpital Européen Georges Pompidou.

2011 – 2013 : Chef de clinique assistant service de transplantation rénale adulte du Pr Ch. Legendre, Hôpital Necker & Université Paris Descartes.

2002 – 2008 : Interne des Hôpitaux, Assistance Publique – Hôpitaux de Paris, Paris

---

## **Mobilite, Sociétés Savantes, Activités Éditoriales**

### **Mobilité**

University of Alberta, Applied Genomic center ATAGC Kidney Transplant Department; Pr Phil Halloran (Novembre 2010 – Novembre 2011).

### **Sociétés savantes et prix**

Strong Together PRO Award : European Society for Organ Transplantation (2017)

Expert auprès de la FDA (Washington, Novembre 2015) section transplantation rénale »

Directeur élu (elected chair) du comité scientifique de la classification internationale de Banff 2015 (Vancouver). Réélection pour la session de 2017 (Barcelone)

Prix de la société de Francophone de Néphrologie (Novembre 2015)

Membre Société Francophone (SFT), Européenne (ESOT) et Américaine (AST) de Transplantation

Young Investigator Award: European Society for Organ Transplantation (2009)

Lauréat de la médaille d'or de l'internat des Hôpitaux de Paris (2008)

### **Activités éditoriales**

Associate Editor pour la revue Transplantation (nommé en Janvier 2014)

Selecteur (referee) pour les revues suivantes : New England Journal of Medicine, Nature Medicine, Lancet, JAMA, American Journal of Transplantation, Journal of the American Society of Nephrology

---

## **PRINCIPALES COLLABORATIONS INTERNATIONALES**

P Halloran, Edmonton, Canada

A Zeevi, Pittsburgh, USA

S Jordan Los Angeles, USA

M Stegal, Rochester USA

D Segev, Baltimore, USA

---

## **FINANCEMENTS DES RECHERCHES**

RHU (8.8 million €) : KTD-Innov : en cours

H2020 (6.6 million €) : EU-TRAIN : en cours

C1q\_compredict (ThermoFischer, 2.2 million €): Complement binding antibodies in kidney transplant: terminé 01/01/2014

Subclass\_Ig allograft injury (One Lambda 400 k€): Predictive value of IgG subclass in allograft rejection: terminé 01/07/2016

National allograft allocation agency (70 k€): Microarray in transplant rejection diagnostics: terminé 01/01/2017

INTERCOM (national Canadian grant, 700 k€). Diagnostic applications of microarray in Transplantation co  
PI: en cours

MIRACLE (institutional APHP grant, 500 k€): MicroRNA non invasive diagnosis of rejection. WP Leader  
end 31/12/2017

---

## Activités d'enseignement

### **Enseignement de Santé publique et économie de la santé à Paris Descartes.**

Depuis septembre 2014 je coordonne l'UE de santé publique qui est destinée aux étudiants en soins infirmiers. Mes missions au sein de cette UE comprennent la mise en place ainsi que la structuration des cours magistraux et des travaux dirigés. Je suis également en charge l'établissement et la correction des sujets d'examens et des enseignements. L'UE santé publique et économie de la santé se déroule sur 2 semestres (S2 et S3), elle comporte 25 heures de cours magistraux et 40 heures de travaux dirigés.

### **Enseignements Dirigés, 2ème Cycle des Etudes Médicales, Université Paris Descartes.**

### **Enseignement de l'épidémiologie Master M2 de Santé Publique Spécialité Recherche en santé publique de l'ED 420.**

Cet enseignement comporte 4 heures de cours magistraux, et 4 heures de TD d'analyse d'article, préparation et correction de sujets d'examens. J'effectue depuis maintenant 5 années cet enseignement sur la thématique des « Analyses de survie en transplantation d'organe ». Je participe également aux séances d'évaluation des étudiants qui consistent en l'analyse critique d'article.

### **Enseignement de la méthodologie et analyse critique d'article aux internes du service de transplantation rénale adulte, hôpital Necker (2011-présent).**

J'ai mis en place cet enseignement dans le service de transplantation depuis ma prise de post de chef de clinique assistant en novembre 2011. Cet enseignement est basé sur l'interprétation et l'analyse d'articles scientifiques. Pour cela, je me sers des articles que j'évalue régulièrement dans le cadre de mes fonctions éditoriales pour la revue American Journal of Transplantation. Les internes participent au processus d'analyse critique de l'article, puis au suivi des correspondances entre éditeurs jusqu'à la décision finale de l'article. Cette méthode apparaît comme très efficace pour l'apprentissage des règles de méthodologie.

### **Conférencier d'internat : La conférence Hippocrate 2003 – 2005**

### **Rédaction d'ouvrages à visée pédagogique**

Participation à la rédaction d'un ouvrage intitulé « La Transplantation Rénale » sous la direction du Professeur Christophe Legendre.

### **Publications en pédagogie (revues)**

Auteur de 3 articles de synthèse, dans des revues de langue anglaise (Nature Reviews, Current Opinion in

Organ Transplantation (Publication en 2011 et 2012 cf chapitre publications) et Official book of the American Society of Transplantation chapitre : « Management of Antibody Mediated Rejection ».

## **Animation scientifique et encadrement du module « Épidémiologie intégrative de la transplantation »**

PARCC HEGP U 970: 2 Demi journées par semaine depuis 2010 et 3 demi journées par semaine depuis novembre 2013.

---

# **PUBLICATIONS**

## **Mémoires de thèse de science**

PhD #1 (Basic science): “PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor” (1 article original publié dans le JCI)

PhD #2 (Epidemiology – biostatistics): “Risk prediction in kidney transplantation: population approach and integrative epidemiology” (3 articles originaux publiés dans Lancet, NEJM et JASN)

## **Articles**

83. Lefaucheur C, Viglietti D, Loupy A. [Recognition of iIF/TA as a component of the T cell-mediated rejection spectrum: Unselected population approach vs random case selection.](#) Am J Transplant. 2018 Jan 17

82. Querard AH, Le Borgne F, Dion A, Giral M, Mourad G, Garrigue V, Rostaing L, Kamar N, Loupy A, Legendre C, Morelon E, Buron F, Foucher Y, Dantan E. [Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors.](#) Am J Transplant. 2018 Jan 9

81. Montgomery RA, Loupy A, Segev DL. [Antibody-mediated rejection: New approaches in prevention and management.](#) Am J Transplant. 2018 Jan;18 Suppl 3:3-17

80. Viglietti D, Loupy A, Aubert O, Bestard O, Van Huyen JD, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C. [Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.](#) J Am Soc Nephrol. 2018 Feb;29(2):606-619

79. Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, Nankivell BJ, Halloran PF, Colvin RB, Akalin E, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell LD, van Huyen JPD, Gibson IW, Kraus ES, Mannon RB, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegall M, Randhawa P, Racusen L, Solez K, Mengel M. [The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.](#) Am J Transplant. 2018 Feb;18(2):293-307

78. Chen CC, Pouliquen E, Broisat A, Andreata F, Racapé M, Bruneval P, Kessler L, Ahmadi M, Bacot S, Saison-Delaplace C, Marcaud M, Van Huyen JD, Loupy A, Villard J, Demuylder-Mischler S, Berney T, Morelon E, Tsai MK, Kolopp-Sarda MN, Koenig A, Mathias V, Ducreux S, Ghezzi C, Dubois V, Nicoletti A, Defrance T, Thaunat O. [Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection.](#) J Clin Invest. 2018 Jan 2;128(1):219-232
77. Lefaucheur C, Gosset C, Rabant M, Viglietti D, Verine J, Aubert O, Louis K, Glotz D, Legendre C, Duong Van Huyen JP, Loupy A. [T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.](#) Am J Transplant. 2018 Feb;18(2):377-390
76. Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A. [Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.](#) J Am Soc Nephrol. 2018 Feb;29(2):620-635
75. Loupy A, Hidalgo L, Duong JP, Bruneval P, Jouven X, Halloran PF. [Response by Loupy et al to Letters Regarding Article, "Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection".](#) Circulation. 2017 Aug 15;136(7):698-699
74. Halloran PF, Potena L, Van Huyen JD, Bruneval P, Leone O, Kim DH, Jouven X, Reeve J, Loupy A. [Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic \(MMDx\) System.](#) J Heart Lung Transplant. 2017 Nov;36(11):1192-1200
73. Reeve J, Böhmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, Halloran PF; MMDx-Kidney study group. [Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.](#) JCI Insight. 2017 Jun 15;2(12)
72. Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C. [Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.](#) Kidney Int. 2017 Sep;92(3):729-742
71. Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen JP, Gupta G, Lefaucheur C, Malone A, Mannon RB, Seron D, Sellares J, Weir M, Loupy A. [Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study.](#) Am J Transplant. 2017 Nov;17(11):2851-2862
70. Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF. [Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.](#) J Am Soc Nephrol. 2017 Jun;28(6):1912-1923
69. Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. [Assessment of Tocilizumab \(Anti-Interleukin-6 Receptor Monoclonal\) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.](#) Am J Transplant. 2017 Sep;17(9):2381-2389

68. Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, Venner JM, Falmuski K, Bories MC, Beuscart T, Guillemain R, François A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X, Halloran PF. [Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection](#). Circulation. 2017 Mar 7;135(10):917-935
67. Lefaucheur C, Viglietti D, Mangiola M, Loupy A, Zeevi A. [From Humoral Theory to Performant Risk Stratification in Kidney Transplantation](#). J Immunol Res. 2017;2017:5201098
66. Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trněčka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. [Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation](#). Transplantation. 2017 Feb;101 Suppl 2S:S1-S41
65. Amrouche L, Aubert O, Suberbielle C, Rabant M, Van Huyen JD, Martinez F, Sberro-Soussan R, Scemla A, Tinel C, Snanoudj R, Zuber J, Cavalcanti R, Timsit MO, Lamhaut L, Anglicheau D, Loupy A, Legendre C. [Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program](#). Transplantation. 2017 Oct;101(10):2440-2448
64. Bruneval P, Angelini A, Miller D, Potena L, Loupy A, Zeevi A, Reed EF, Dragun D, Reinsmoen N, Smith RN, West L, Tebutt S, Thum T, Haas M, Mengel M, Revelo P, Fedrigo M, Duong Van Huyen JP, Berry GJ. [The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions](#). Am J Transplant. 2017 Jan;17(1):42-53
63. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, Nankivell BJ, Colvin RB, Afrouzian M, Akalin E, Alachkar N, Bagnasco S, Becker JU, Cornell L, Drachenberg C, Dragun D, de Kort H, Gibson IW, Kraus ES, Lefaucheur C, Legendre C, Liapis H, Muthukumar T, Nickeleit V, Orandi B, Park W, Rabant M, Randhawa P, Reed EF, Roufosse C, Seshan SV, Sis B, Singh HK, Schinstock C, Tambur A, Zeevi A, Mengel M. [The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology](#). Am J Transplant. 2017 Jan;17(1):28-41
62. Cassuto E, Pageaux GP, Cantarovich D, Rostaing L, Loupy A, Roche B, Duvoux C, Moreau K, Thervet E, Mazouz H, Bourhis Y, Dharancy S, Kessler M; OSIRIS investigators. [Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study](#). Transplantation. 2016 Oct;100(10):2099-2106
61. Jabre P, Bougouin W, Dumas F, Carli P, Antoine C, Jacob L, Dahan B, Beganton F, Empana JP, Marijon E, Karam N, Loupy A, Lefaucheur C, Jost D, Cariou A, Adnet F, Rea TD, Jouven X. Early Identification of Patients With Out-of-Hospital Cardiac Arrest With No Chance of Survival and Consideration for Organ Donation. Ann Intern Med. 2016 Dec 6;165(11):770-778
60. Weissenbacher A, Loupy A, Chandraker A, Schneeberger S. [Donor-specific antibodies and antibody-mediated rejection in vascularized composite allotransplantation](#). Curr Opin Organ Transplant. 2016 Oct;21(5):510-5

59. Viglietti D, Loupy A, Vernerey D, Bentlejewski C, Gosset C, Aubert O, Duong van Huyen JP, Jouven X, Legendre C, Glotz D, Zeevi A, Lefaucheur C. [Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.](#) J Am Soc Nephrol. 2017 Feb;28(2):702-715
58. Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, Glotz D, Lefaucheur C. [C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.](#) Am J Transplant. 2016 May;16(5):1596-603
57. Loupy A, Toquet C, Rouvier P, Beuscart T, Bories MC, Varnous S, Guillemain R, Pattier S, Suberbielle C, Leprince P, Lefaucheur C, Jouven X, Bruneval P, Duong Van Huyen JP. [Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.](#) Am J Transplant. 2016 Jan;16(1):111-20
56. Canaud G, Loupy A. [Focal Segmental Glomerulosclerosis Recurrence: Soluble Urokinase Receptor Left Out?](#) Transplantation. 2015 Dec;99(12):2449-50
55. Lefaucheur C, Viglietti D, Bentlejewski C, Duong van Huyen JP, Vernerey D, Aubert O, Verine J, Jouven X, Legendre C, Glotz D, Loupy A, Zeevi A. [IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.](#) J Am Soc Nephrol. 2016 Jan;27(1):293-304
54. Aubert O, Kamar N, Vernerey D, Viglietti D, Martinez F, Duong-Van-Huyen JP, Eladari D, Empana JP, Rabant M, Verine J, Rostaing L, Congy N, Guilbeau-Frugier C, Mourad G, Garrigue V, Morelon E, Giral M, Kessler M, Ladrière M, Delahousse M, Glotz D, Legendre C, Jouven X, Lefaucheur C, Loupy A. [Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study.](#) BMJ. 2015 Jul 31;351:h3557
53. Loupy A, Vernerey D, Viglietti D, Aubert O, Duong Van Huyen JP, Empana JP, Bruneval P, Glotz D, Legendre C, Jouven X, Lefaucheur C. [Determinants and Outcomes of Accelerated Arteriosclerosis: Major Impact of Circulating Antibodies.](#) Circ Res. 2015 Aug 14;117(5):470-82
52. Loupy A, Legendre C. [From Mean Fluorescence Intensity to C1q-Binding: The Saga of Anti-HLA Donor-specific Antibodies.](#) Transplantation. 2015 Jun;99(6):1107-8
51. Loupy A, Viglietti D, Mengel M. [Complement inhibition in HLA-incompatible kidney transplants: persisting antibody-mediated injury despite marked decrease of clinical ABMR.](#) Am J Transplant. 2015 May;15(5):1139-40
50. Loupy A, Vernerey D, Tiné C, Aubert O, Duong van Huyen JP, Rabant M, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C. [Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.](#) J Am Soc Nephrol. 2015 Jul;26(7):1721-31
49. Legendre C, Loupy A, Rabant M, Aubert O, Rabaté C, Delville M, Tiné C, Amrouche L, Martinez F, Snanoudj R, Bererhi L, Scemla A, Sberro-Soussan R, Duong JP, Suberbielle C, Anglicheau D. [\[Current aspects of acute humoral rejection\].](#) Nephrol Ther. 2014 Nov;10(6):479-83
48. Chemouny JM, Suberbielle C, Rabant M, Zuber J, Alyanakian MA, Lebreton X, Carmagnat M, Pinheiro N, Loupy A, Van Huyen JP, Timsit MO, Charron D, Legendre C, Anglicheau D. [De Novo Donor-Specific Human](#)

[Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection.](#)  
Transplantation. 2015 May;99(5):965-72

47. Viglietti D, Abboud I, Hill G, Vernerey D, Nochy D, Antoine C, Fieux F, Assayag M, Verine J, Gaudez F, Loupy A, Glotz D, Lefaucheur C. [Kidney allograft fibrosis after transplantation from uncontrolled circulatory death donors.](#) Transplantation. 2015 Feb;99(2):409-15

46. Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, Iserin F, Rouvier P, François A, Vernerey D, Loyer X, Leprince P, Empana JP, Bruneval P, Loupy A, Jouven X. [MicroRNAs as non-invasive biomarkers of heart transplant rejection.](#) Eur Heart J. 2014 Dec 1;35(45):3194-202

45. Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, Verine J, Aubert O, Dubleumortier S, Duong van Huyen JP, Jouven X, Glotz D, Legendre C, Halloran PF. Molecular Microscope Strategy To Improve Risk Stratification In Early Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol. 2014 Oct;25(10):2267-77

44. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, Castro MC, David DS, David-Neto E, Bagnasco SM, Cendales LC, Cornell LD, Demetris AJ, Drachenberg CB, Farver CF, Farris AB 3rd, Gibson IW, Kraus E, Liapis H, Loupy A, Nickeleit V, Randhawa P, Rodriguez ER, Rush D, Smith RN, Tan CD, Wallace WD, Mengel M; Banff meeting report writing committee. [Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.](#) Am J Transplant. 2014 Feb;14(2):272-83

43. Lefaucheur C, Loupy A, Zeevi A. [Complement-binding anti-HLA antibodies and kidney transplantation.](#) N Engl J Med. 2014 Jan 2;370(1):85-6

42. Zaidan M, Loupy A, Rouquette A, Philippe Massault P, Martinez F, Legendre C, Mamzer-Bruneel MF. [A kidney transplant patient with ileocecal inflammation. Sodium polystyrene sulfonate-associated intestinal ulcer and foreign-body reaction.](#) Kidney Int. 2013 Nov;84(5):1057-9

41. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X. [Complement-binding anti-HLA antibodies and kidney-allograft survival.](#) N Engl J Med. 2013 Sep 26;369(13):1215-26

40. Tible M, Loupy A, Vernerey D, Suberbielle C, Beuscart T, Cazes A, Guillemain R, Amrein C, Pezzella V, Fabiani JN, Nochy D, Hill G, Empana JP, Jouven X, Charron D, Bruneval P, Duong Van Huyen JP. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung Transplant. 2013 Aug;32(8):769-76

39. Legendre C, Sberro-Soussan R, Zuber J, Rabant M, Loupy A, Timsit MO, Anglicheau D. [Eculizumab in renal transplantation.](#) Transplant Rev (Orlando). 2013 Jul;27(3):90-2

38. Loupy A, Lefaucheur C, Glotz D, Legendre C, Jouven X. [Diagnostic criteria for kidney transplant rejection: a call to action - Authors' reply.](#) Lancet. 2013 Apr 27;381(9876):1458-9

37. Sellarés J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kleepala C, Hidalgo LG, Famulski KS, Halloran PF. [Molecular diagnosis of antibody-mediated rejection in human kidney transplants](#). Am J Transplant. 2013 Apr;13(4):971-983
36. Loupy A, Jordan SC. [Transplantation: Donor-specific HLA antibodies and renal allograft failure](#). Nat Rev Nephrol. 2013 Mar;9(3):130-1
35. Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Simula-Faivre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Borg C, Saas P, Ducloux D. [Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation](#). Transplantation. 2013 Mar 15;95(5):728-32
34. Lefaucheur C\*, Loupy A\*, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, Vérine J, Beuscart T, Nochy D, Bruneval P, Charron D, Delahousse M, Empana JP, Hill GS, Glotz D, Legendre C, Jouven X. [Antibody-mediated vascular rejection of kidney allografts: a population-based study](#). Lancet. 2013 Jan 26;381(9863):313-9. \* Shared first authorship
33. Loupy A, Ramakrishnan SK, Wootla B, Chambrey R, de la Faille R, Bourgeois S, Bruneval P, Mandet C, Christensen EI, Faure H, Cheval L, Laghmani K, Collet C, Eladari D, Dodd RH, Ruat M, Houillier P. [PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor](#). J Clin Invest. 2012 Sep;122(9):3355-67
32. Loupy A, Hill GS, Jordan SC. [The impact of donor-specific anti-HLA antibodies on late kidney allograft failure](#). Nat Rev Nephrol. 2012 Apr 17;8(6):348-57
31. El Karoui K, Hill GS, Karras A, Jacquot C, Moulouquet L, Kourilsky O, Frémeaux-Bacchi V, Delahousse M, Duong Van Huyen JP, Loupy A, Bruneval P, Nochy D. [A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy](#). J Am Soc Nephrol. 2012 Jan;23(1):137-48
30. Loupy A, Vernerey D, Hill GS, Legendre Ch, Anglicheau D. [Delineating the picture of renal graft injury in 2011](#). Am J Transplant. 2011 Aug;11(8):1757
29. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, Pezzella V, Fabiani JN, Suberbielle C, Nochy D, Hill GS, Empana JP, Jouven X, Bruneval P, Duong Van Huyen JP. [Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy](#). Am J Transplant. 2011 Jul;11(7):1478-87
28. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, Zuber J, Anglicheau D, Empana JP, Legendre C, Loupy A. [Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation](#). J Am Soc Nephrol. 2011 May;22(5):975-83
27. Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, Timsit MO, Duong JP, Bruneval P, Vernerey D, Empana JP, Jouven X, Nochy D, Legendre CH. [Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies \(DSA\)](#). Am J Transplant. 2011 Jan;11(1):56-65

26. El Karoui K, Hill GS, Karras A, Moulouguet L, Caudwell V, Loupy A, Bruneval P, Jacquot C, Nochy D. [Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.](#) Kidney Int. 2010
25. Scemla A, Loupy A, Candon S, Mamzer MF, Martinez F, Zuber J, Sberro R, Legendre C, Thervet E. [Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study.](#) Transplantation. 2010 Dec 15;90(11):1180-4
24. Timsit MO, Nguyen KN, Rouach Y, Elie C, Loupy A, Fournier C, Legendre C, Mejean A. [Kidney function following nephrectomy: similitude and discrepancies between kidney cancer and living donation.](#) Urol Oncol. 2012 Jul-Aug;30(4):482-6
23. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C. [Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.](#) J Am Soc Nephrol. 2010 Aug;21(8):1398-406
22. Aubin F, Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Humbert P, Saas P, Ducloux D. [Influence of cyclooxygenase-2 \(COX-2\) gene promoter polymorphism at position -765 on skin cancer after renal transplantation.](#) J Invest Dermatol. 2010 Aug;130(8):2134-6
21. Loupy A, Suberbielle-Boissel C, Zuber J, Anglicheau D, Timsit MO, Martinez F, Thervet E, Bruneval P, Charron D, Hill GS, Nochy D, Legendre C. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010 Jun 15;89(11):1403-10
20. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, Anglicheau D, Leruez M, Loupy A, Thervet E, Hermine O, Legendre C. [Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies.](#) Am J Transplant. 2010 Mar;10(3):681-6
19. Loupy A, Hill GS, Nochy D, Legendre C. [Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.](#) Am J Transplant. 2010 Apr;10(4):952
18. Legendre Ch, Kreis H, Martinez F, Snanoudj R, Mamzer MF, Sberro R, Bererhi L, Anglicheau D, Zuber J, Loupy A, Thervet E, Pallet N, Sartorius A, Bertrand D, Canaud G, Noël LH, Rabant M, Timsit MO, Méjean A. [Kidney transplantation at Necker Hospital: the most recent 5-year period \(2004-2009\).](#) Clin Transpl. 2010:127-32
17. Disset A, Cheval L, Soutourina O, Duong Van Huyen JP, Li G, Genin C, Tostain J, Loupy A, Doucet A, Rajerison R. [Tissue compartment analysis for biomarker discovery by gene expression profiling.](#) PLoS One. 2009 Nov 10;4(11):e7779
16. Hill GS, Nochy D, Loupy A. [Accelerated arteriosclerosis: a form of transplant arteriopathy.](#) Curr Opin Organ Transplant. 2010 Feb;15(1):11-5

15. Snanoudj R, Rabant M, Timsit MO, Karras A, Savoye E, Tricot L, Loupy A, Hiesse C, Zuber J, Kreis H, Martinez F, Thervet E, Méjean A, Lebret T, Legendre C, Delahousse M. [Donor-estimated GFR as an appropriate criterion for allocation of ECD kidneys into single or dual kidney transplantation](#). Am J Transplant. 2009 Nov;9(11):2542-51
14. Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D. [Influence of cyclooxygenase-2 \(COX-2\) gene promoter polymorphism -765 on graft loss after renal transplantation](#). Am J Transplant. 2009 Dec;9(12):2752-7
13. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Anglicheau D, Zuber J, Martinez F, Thervet E, Méjean A, Charron D, Duong van Huyen JP, Bruneval P, Legendre C, Nochy D. [Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies](#). Am J Transplant. 2009 Nov;9(11):2561-70
12. Anglicheau D\*, Loupy A\*, Lefaucheur C, Pessone F, Létourneau I, Côté I, Gaha K, Noël LH, Patey N, Droz D, Martinez F, Zuber J, Glotz D, Thervet E, Legendre C. [A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors](#). Am J Transplant. 2008 Nov;8(11):2325-34 \* Shared first authorship
11. Loupy A, Join-Lambert OF, Bébéar CM, Legendre C, Anglicheau D. [Urogenital mycoplasma: an emerging cause of deep wound infection after kidney transplantation?](#) NDT Plus. 2008 Aug;1(4):239-40
10. Bollée G, Anglicheau D, Loupy A, Zuber J, Patey N, Mac Gregor D, Martinez F, Mamzer-Bruneel MF, Snanoudj R, Thervet E, Legendre C, Noël LH. [High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients](#). Clin J Am Soc Nephrol. 2008 Sep;3(5):1461-8
9. Loupy A, Laissy JP, Klein I, Bachir D, Bouadma L, Wolff M, Regnier B, Pease S. [Fat emboli unleashed: an exceptional etiology of encephalitis in sickle cell disease](#). Ann Hematol. 2008 Nov;87(11):939-41
8. Loupy A, Messika-Zeitoun D, Cachier A, Himbert D, Brochet E, Lung B, Vahanian A. [An unusual cause of pacemaker-induced severe tricuspid regurgitation](#). Eur J Echocardiogr. 2008 Jan;9(1):201-3
7. Loupy A, Anglicheau D, Suberbielle C, Méjean A, Martinez F, Zuber J, Mamzer-Bruneel MF, Kreis H, Thervet E, Thiounn N, Legendre C. [Long-term outcome of third kidney transplants](#). Nephrol Dial Transplant. 2007 Sep;22(9):2693-700
6. Loupy A, Pouchot J, Hertig A, Bonnard G, Bouvard E, Rondeau E. [\[Massive rhabdomyolysis revealing a McArdle disease\]](#). Rev Med Interne. 2007
5. Anglicheau D, Loupy A, Suberbielle C, Zuber J, Patey N, Noël LH, Cavalcanti R, Le Quintrec M, Audat F, Méjean A, Martinez F, Mamzer-Bruneel MF, Thervet E, Legendre C. [Posttransplant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: a pilot study](#). Am J Transplant. 2007 May;7(5):1185-92

4. Loupy A, Anglicheau D, Timsit MO, Thervet E, Mamzer-Bruel MF, Martinez F, Desgranchamps F, Thioune N, Kreis H, Legendre C, Chrétien Y, Méjean A. [Impact of surgical procedures and complications on outcomes of third and subsequent kidney transplants.](#) Transplantation. 2007 Feb 27;83(4):385-91
3. Loupy A, Anglicheau D, Mamzer-Bruel MF, Martinez F, Thervet E, Legendre C, Serpaggi J, Pol S. [Mycophenolate sodium-induced hepatotoxicity: first report.](#) Transplantation. 2007 Feb 27;83(4):385-91
2. Loupy A, Anglicheau D, Mamzer-Bruel MF, Martinez F, Thervet E, Legendre C, Serpaggi J, Pol S. [Mycophenolate sodium-induced hepatotoxicity: first report.](#) Transplantation. 2006 Aug 27;82(4):581
1. Loupy A, Guignard S, Manceron V, Pouchot J, Vinceneux P. [\[Contiguous Pseudomonas aeruginosa sacro-iliitis\].](#) Rev Med Interne. 2003 Dec;24(12):843-5

---

## Communications orales congrès internationaux

Depuis 2006, 32 communications orales dont 6 communications en séance plénière

### European Society of Organ Transplantation 2017

A Loupy. What to do when randomized controlled trials stop working. Plenary session

A Loupy. Time to make computer-assisted instead of eminence-based decisions?

A Loupy, O Aubert, B Orandi, A Jackson, M Naessens, N Kamar, O Thaunat, E Morelon, M Delahousse, D Viglietti, C Legendre, D Glotz, X Jouven, RA Montgomery, M Stegall, DL Segev, C Lefaucheur. A Multidimensional Prognostic Score and Nomogram to Predict Kidney Transplant Survival: The Integrative Box (IBOX) System

### American Transplant Congress (ATC) 2017

A Loupy, JP Duong Van Huyen, L Hidalgo, J Reeve, M Racapé, O Aubert, J Venner, D Viglietti, P Bruneval, C Lefaucheur, PF Halloran. Gene Expression Profiling For The Identification And Classification of Antibody-Mediated Heart Rejection

### International Society for Heart and Lung Transplantation 2016

A. Loupy. Precision Medicine in Organ Transplantation: Moving from Off the Rack to Bespoke. Plenary session

### American Transplant Congress 2015

A. Loupy, C. Lefaucheur, D. Vernerey, J. Chang, L. Hidalgo, J. Duong, X. Jouven, D. Glotz, C. Legendre, P. Halloran. Molecular Microscope for disease activity and stage in heart ABMR. Plenary session

### **European Society of Cardiology 2014**

A. Loupy, M. Tible, D. Vernerey, P. Rouvier, S. Varnous, R. Guillemain, C. Lefaucheur, X. Jouven, P. Bruneval, J. Duong, X. Jouven. miRNAs as Biomarkers for Heart Transplant Rejection. Plenary session.

### **American Transplant Congress 2014**

A. Loupy, D. Vernerey, C. Tinel, J. Duong, M. Rabant, X. Jouven, D. Glotz, C. Legendre, C. Lefaucheur. Early Recognition of Subclinical Rejection and Outcome of Kidney Allografts

A. Loupy, C. Lefaucheur, D. Vernerey, J. Chang, L. Hidalgo, J. Duong, X. Jouven, D. Glotz, C. Legendre, P. Halloran. Molecular Microscope Strategy To Improve Risk Stratification in ABMR.

A. Loupy, C. Toquet, D. Vernerey, P. Rouvier, S. Varnous, M. Tible, T. Beuscart, C. Lefaucheur, P. Bruneval, J. Duong. Paris Translational Research. Characterization of a Specific Mechanism for Late Loss of Cardiac Allograft: The Role of Antibody-Mediated Rejection

A. Loupy, C. Lefaucheur, D. Vernerey, J. Duong, O. Aubert, M. Rabant, X. Jouven, D. Glotz, C. Legendre, Post Transplant DSA: Independent Factor of Accelerated Arteriosclerosis in Kidney Transplant Population.

A. Loupy, T. Beuscart, C. Lefaucheur, J. Reeve, L. Hidalgo, J. Chang, A. Gay, A. François, S. Varnous, MC. Bories, R. Guillemain, P. Bruneval, X. Jouven, JP. Duong, PF. Halloran. The Molecular Phenotype Of Antibody-Mediated Rejection In Heart Transplants.

A. Loupy, C. Lefaucheur, J. Reeve, L. Hidalgo, K. Falmuski, JP. Duong, J. Chang, O. Aubert,

A. Zeevi, X. Jouven, D. Glotz, C. Legendre, P. Halloran. Session: "Plenary Session - C1q-Binding DSA Induce Distinct Molecular Phenotypes In Kidney Transplant Biopsies."

### **American Transplant Congress 2013**

A. Loupy, C. Lefaucheur, D. Vernerey, J. Chang, LG. Hidalgo, Ch. Legendre, PF. Halloran. Molecular Microscope Strategy To Improve Risk Stratification In Early Antibody-Mediated Kidney Allograft Rejection.

### **American Transplant Congress 2012**

A. Loupy, Hidalgo L, Sellares J, Reeve J, Legendre C, Halloran P: Significance of NK<sub>B</sub> in kidney transplants with DSA.

A. Loupy, Hidalgo L, Sellares J, Reeve J, Legendre C, Halloran P: determinants of outcome in ABMR : a clinical – histological and molecular approach.

A Loupy, Vernerey D, Anglicheau D, Empana JP, Jouven X, Legendre C, Clinical relevance of screening biopsy in transplantation.

### **European Society of Cardiology 2011**

A Loupy, D Vernerey et al : Outcome of very late heart transplant rejection.

### **American Transplant Congress 2011**

A Loupy, C Lefaucheur, et al: Therapeutic consequences of vascular rejection with DSA. .

A Loupy, C Lefaucheur et al: Vascular rejection with DSA : clinical characteristics and immunology.

### **American Transplant Congress 2010**

A Loupy, G S Hill, C Suberbielle, D Anglicheau, JP Duong, J Zuber, J Posson, MF Mamzer, F Martinez, E Thervet, P Bruneval, D Nochy, C Legendre. Significance of minimal and Focal C4d In stable DSA+ Kidney transplant Recipients.

A Loupy, A Cazes, R Guillemain, C Amrein, A Hedjoudje, V Pezzella, G S Hill, D Nochy, P Bruneval, JP Duong van Huyen. Very late heart transplant rejection is associated with capillary complement deposition and microcirculation inflammation.

A Loupy, G S Hill, P Bruneval, D Glotz, D Anglicheau, J Zuber, F Martinez, E Thervet, C Legendre, D Nochy. Accelerated Progression of Arteriosclerosis in kidney transplant patients with preformed donor specific anti-HLA antibodies.

A Loupy, C Lefaucheur, C Suberbielle, D Glotz : Long term outcome according to levels of pretransplant DSA in kidney recipients.

### **European Society of Organ Transplantation ESOT 2009**

A Loupy, S Escolano, D Anglicheau, G Friedlander, X Jouven, C Legendre, M Froissart. Differential evolution of structural and functional changes during the first year of kidney transplantation.

A Loupy, C Lefaucheur, C Suberbielle, G Hill, C Legendre and D Nochy. Natural history of subclinical antibody-mediated rejection (SC AMR) in kidney transplant recipients (KTR) with preexisting DSAs.

### **American Society of Nephrology 2009**

A Loupy, R Chambrey, B Wootla, L Cheval, M Ruat, P Houillier: Localization and functional expression of calcium sensing receptor CaSR in the Kidney.

### **American Transplant Congress 2009**

A Loupy, S Escolano, D Anglicheau, G Friedlander, X Jouven, C Legendre, M Froissart. Differential evolution of structural and functional changes during the first year of kidney transplantation.

A Loupy, C Suberbielle, D Anglicheau, D Nochy, G Hill, C Legendre. Prophylactic anti-CD20 combined with plasmapheresis (PP) reduces chronic AMR in kidney transplant recipients (KTR) with preexisting DSAs.

A Loupy, C Lefaucheur, C Suberbielle, G Hill, C Legendre and D Nochy. Natural history of subclinical antibody-mediated rejection (SC AMR) in kidney transplant recipients (KTR) with preexisting DSAs.

#### **American Transplant Congress 2008**

A Loupy, D Anglicheau, C Legendre. A simple composite clinicopathological score is highly predictive of graft outcome in marginal donors.

#### **American Transplant Congress 2007**

A Loupy, F Martinez, L Bergougnoux, M Hourmant, L Rostaing, D Durand, G Mourad, M Kessler, C Legendre, J-P Soulillou. Kidney Transplantation In The Elderly: A European Multicentric Experience.

#### **World Transplant Congress 2006**

A Loupy, D Anglicheau, MO Timsit, E Thervet, F Desgranchamps, C Legendre, Y Chrétien, A Méjean. Technical Aspects, Surgical Complications, And Outcome Of Third And Subsequents Kidney Transplants.

A Loupy, D Anglicheau, C S, A Méjean, F Martinez, J Zuber, MF Mamzer-Bruneel, E Thervet, N Thiounn, C Legendre. Long-Term Outcome Of Third Kidney Transplants.

A Loupy, M Froissart, M Flamant, E Thervet, C Legendre. Predictive Performance of Abbreviated MDRD and Cockcroft and Gault (CG) Formulas for Estimating Glomerular Filtration Rate (eGFR) during the first year of Kidney Transplantation.